Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors

Clinical Cancer Research

Volumn 13, Issue 5, 2007, Pages 1480-1487

  Martin, Darryl T ^a   Gendron, Robert L ^a   Jarzembowski, Jason A ^b   Perry, Arie ^c   Collins, Margaret H ^d   Pushpanathan, Chitra ^a   Miskiewicz, Ewa ^a   Castle, Valerie P ^b   Paradis, Hélène ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN TUBEDOWN; RETINOIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GANGLIONEUROMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACETYLTRANSFERASES; BLOTTING, WESTERN; BRAIN NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEUROBLASTOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33947424032     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1716     Document Type: Article

References (33)

1. Castel V, Canete A. A comparison of current neuroblastoma chemotherapeutics. Expert Opin Pharmacother 2004;5:71-80.
2. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 2004;325:1-15.
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
4. Maris JM. The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 2005;17:7-13.
5. Vasudevan SA, Nuchtern JG, Shohet JM. Gene profiling of high risk neuroblastoma. World J Surg 2005;29: 317-24.
6. Browne M, Kletzel M, Cohn SL, et al. Excellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma. J Pediatr Surg 2006;41:271-6.
7. Laverdiere C, Cheung NKV, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005;45:324-32.
8. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999a;86:349-63.
9. Shimada H, Ambros IM, Dehner LP, et al.The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999b;86:364-72.
10. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003;197:185-92.
11. Gendron RL, Adams LC, Paradis H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev Dyn 2000;218:300-15.
12. Fluge O, Bruland O, Akslen LA, et al. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 2002;21:5056-68.
13. Willis DM, Loewy AP, Charlton-Kachigian N, et al. Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex. J Biol Chem 2002;277:37280-91.
14. Sugiura N, Adams SM, Corriveau RA. An evolutionary conserved N-terminal acetyltransferase complex associated with neuronal development. J Biol Chem 2003;278:40113-20.
15. Gendron RL, Good WV, Adams LC, et al. Suppressed expression of tubedown-1 in retinal neovascularization of proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2001;42:3000-7.
16. Arnesen T, Gromyko D, Horvli O, et al. Expression of N-acetyl transferase human and human arrest defective 1 proteins in thyroid neoplasms. Thyroid 2005;15: 1131-6.
17. Paradis H, Liu CY, Saika S, et al. Tubedown-1 in remodeling of the developing vitreal vasculature in vivo and regulation of capillary outgrowth in vitro. Dev Biol 2002;249:140-55.
18. Wall DS, Gendron RL, Good WV, et al. Conditional knockdown of tubedown-1 in endothelial cells leads to neovascular retinopathy. Invest Ophthalmol Vis Sci 2004;45:3704-12.
19. Arnesen T, Gromyko D, Pendino F, et al. Induction of apoptosis in human cells by RNAi-mediated knock-down of hARD1 and NATH, components of the protein N-α-acetyltransferase complex. Oncogene 2006;25:4350-60.
20. Bridge RS, Rajaram V, Dehner LP, et al. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod Pathol 2006;19:1-8.
21. Seeger RC, Danon YL, Rayner SA, et al. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, and teratoma cells with a monoclonal antibody. J Immunol 1982;128:983-9.
22. Tumilowicz JJ, Nichols WW, Cholon JJ, et al. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 1970;30:2110-8.
23. Gendron RL, Good WV, Miskiewicz E, et al. Tubedown-1 suppression in oxygen-induced retinopathy and in retinopathy of prematurity. Mol Vis 2006;22: 108-16.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53: 457-81.
25. Krams M, Parwaresch R, Sipos B, et al. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis. Oncogene 2004;23:588-95.
26. Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma-a novel independent prognostic factor. Ann Oncol 2005;16:314-21.
27. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005;23: 6459-65.
28. Joshi VV. Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatr Dev Pathol 2000;3:184-99.
29. Matthay KK. MYCN expression in neuroblastoma: a mixed message? J Clin Oncol 2000;18:3591-4.
30. Tang XX, Zhao H, Kung B, et al. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006;66:2826-33.
31. Polevoda B, Sherman F. Composition and function of the eukaryotic N-terminal acetyltransferase subunits. Biochem Biophys Res Commun 2003;308:1-11.
32. Gautschi M, Just S, Mun A, et al. The yeast N(α)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. Mol Cell Biol 2003;23:7403-14.
33. Wang X, Connelly JJ, Wang CL, et al. Importance of the Sir3 N terminus and its acetylation for yeast transcriptional silencing. Genetics 2004;168:547-51.